OBJECTIVES: To report real-world data of a cohort patients treated with immune-checkpoint inhibitors in Brazil, focus immune-related adverse events. MATERIAL AND METHODS: In this retrospective study, we analyzed metastatic solid tumors at an oncology reference center least one dose (given as monotherapy or combination other agents). The safety pro?le was characterized through the incidence even...

Management of Graves' orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients. Rituximab is a monoclonal antibody against CD20 antigen that is expressed in mature and immature B cells. Early experience with rituximab suggests that it is a promising alternative therapy for Graves' orbitopathy. Here we report a case ...

Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mechanisms of the disease. Treatment should rely on a thorough assessment of the activity and severity of GO and its impact on the patient's quality of life. Local measures (artific...

objective(s) recent studies on human indicate that the introduction of therapeutic use of tolerogenic dendritic cell (dc) for chronic inflammatory conditions is imminent. for the purpose of defining cgrp potency in tolerogenic dc production, we investigated the phenotype and il-'2 production of dcs generated from the monocytes of rheumatoid arthritis (ra) patients in the presence of the ca...

PURPOSE To investigate an association between the levels of serum thyroid-stimulating hormone (TSH)-receptor autoantibodies (TRAbs) and Graves' orbitopathy (GO) activity/severity scores, and compare the performance of three different TRAb assays in assessing the clinical manifestations of GO. MATERIALS AND METHODS Cross-sectional study. Medical records of 155 patients diagnosed with GO betwee...

The TSH receptor (TSHR) is the critical target for antibody production in Graves' disease (GD). Insulin-like growth factor 1 receptor (IGF1R) has been proposed as a second autoantigen in complications of GD such as orbitopathy. We attempted to induce orbital tissue remodeling in mice undergoing immunizations with plasmids encoding TSHR and IGF1R delivered by in vivo skeletal muscle electroporat...

Background Graves disease (GD) has increased in prevalence over the past decade in Africa. Despite this, the condition is not well described, especially in sub-Saharan Africa. Objective We have described the clinical characteristics and associated factors of GD in a cohort of patients attending a resource-limited setting tertiary hospital. Methods Patients were examined thoroughly and syste...

objective: the autoimmune diseases tend to coexist with diabetes mellitus type i (t1dm). the concomitance of these two types of diseases will lead to poor glycemic control beside their own complications. in this study the prevalence of thyroid disorder and celiac disease among t1dm patients in yazd, iran was evaluated. materials and methods: all the patients diagnosed as t1dm in yazd younger th...

The authors present the endoscopic intranasal orbital decompression, one of the surgical techniques used for orbital decompression. It can be applied for various indications. The most common indications are: maxillo-facial trauma, orbital haemorrhage, subperiorbital abscess as the complication of sinusitis, optic neuropathy, thyroidassociated orbitopathy (Graves’ orbitopathy). The authors concl...

The clinical utility of the functional TSH receptor autoantibodies was prospectively evaluated in patients with thyroid-associated orbitopathy (TAO). Ophthalmic, endocrine, and serological investigations were performed in 101 consecutive patients with severe and active TAO. Serum thyroid stimulating (TSAb) and blocking (TBAb) antibody levels were measured with two bioassays using cells that exp...